Therapeutic Option of Adding Bevacizumab to Paclitaxel after Treatment Failure for Patients with Metastatic Breast Cancer: Case Reports and Literature Review

Kazuhiko Sato1*, Hiromi Fuchikami1, Naoko Takeda1 and Masaru Iwai2

1Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Japan
2Department of Pharmacy, Tokyo-West Tokushukai Hospital, Japan

Abstract

Introduction: Adding bevacizumab can change an impaired blood supply after resistance to weekly paclitaxel for metastatic breast cancer (MBC). We experienced effective tumor management by adding bevacizumab to paclitaxel refractory disease.

Case 1: A 70-year-old female had multiple lymph-node metastases. After seven months of paclitaxel, she received bevacizumab additional to paclitaxel due to disease progression. Tumor markers were gradually reduced over five months.

Case 2: A 50-year-old female developed lymph-node metastases and multiple bone metastases were also revealed later. After 16 months of paclitaxel, tumor markers were gradually reduced over the next 12 months by also using bevacizumab.

Case 3: A 45-year-old woman had received neoadjuvant chemotherapy using anthracyclines and weekly paclitaxel. During post mastectomy radiation therapy, left chest wall recurrence, lung metastases, and liver metastases were found. Although the interval between paclitaxel monotherapy and paclitaxel plus bevacizumab was only three months, tumor markers were reduced over four months.

Case 4: A 42-year-old woman had been referred due to left inflammatory breast cancer; she had been using anthracyclines and weekly paclitaxel. Left chest wall recurrence and lymph node metastases were found after neoadjuvant chemotherapy. Although the interval between paclitaxel monotherapy and paclitaxel plus bevacizumab was only five months, tumor markers were reduced over the next five months.

Discussion: It was difficult to draw any conclusions regarding the efficacy of adding bevacizumab from this retrospective case series. However, the strategy of additional bevacizumab should be considered and may change the clinical practice for patients with MBC.

Keywords: Metastatic breast cancer; Paclitaxel; Bevacizumab; Resistance; Quality of life
negative MBC, combination chemotherapies such as paclitaxel plus gemcitabine [2] and capecitabine plus docetaxel [3] have been reported to improve overall survival (OS). However, although combination chemotherapies are more effective than when the same agents are administered sequentially, they are usually associated with increased toxicity such as a significant detrimental effect on white cell counts, increased alopecia, and nausea and vomiting [4]. Therefore, whether combination regimens are more effective than single agents when given sequentially is unclear in terms of QOL, suggesting that a sequential monotherapy should be used unless there is rapid disease progression [4]. Bevacizumab (Genentech, South San Francisco, CA) is a recombinant humanized monoclonal antibody to all vascular endothelial growth factor (VEGF-A) isoforms. An initial therapy of paclitaxel plus bevacizumab for MBC has been reported to prolong progression-free survival (PFS) and increase the objective response rate with minimal toxicities [5]. Bevacizumab plus other chemotherapy drugs has also been proved to improve PFS in a first-line setting for patients with MBC by AVADO and RIBBON–1 trials [6,7] and in a second-line setting by the BIBBON–2 trial [8]. However, the indication of bevacizumab for patients with MBC was approved with a concomitant use of paclitaxel only in Japan. In a clinical practice, there may not be many patients who benefit from paclitaxel plus bevacizumab in terms of a high response rate to reduce a large tumor burden in early-line chemotherapy, and prolonging the PFS was a most important benefit of paclitaxel with bevacizumab, as proved by several clinical trials. Although the addition of bevacizumab to paclitaxel achieved no significant adverse effects on health-related QOL compared with paclitaxel alone [9], it is still unclear whether the addition of bevacizumab with its expensive medical cost and potential side effects has an OS benefit [10]. Given that a paclitaxel monotherapy is usually considered as the first-line setting, another chemotherapeutic regimen should be introduced after developing paclitaxel resistance.

Several mechanisms of chemotherapy resistance in solid tumors have been reported at the cellular level, such as functional gene mutations or other changes that influence uptake, metabolism, and export of drugs from cancer cells. The tumor microenvironment also mediates the resistance of chemotherapy because it is related to drug distribution to cancer cells through the tumor vasculature [11]. Patients with MBC are usually treated with a single agent paclitaxel given on a weekly schedule as a front-line therapy, because it appears to offer better PFS than a tri weekly schedule [12,13] or an ixabepilone treatment, and less hematologic toxicity was observed than with nab-paclitaxel [13,14]. Such a low-dose of paclitaxel might cause limited cell death but it also leads to reductions in tumor density and interstitial fluid pressure (IFP) that enhances drug distribution [15]. Therefore, a potential strategy to modify the resistance of weekly paclitaxel is to change the impaired blood supply to the tumor because drug activity to the tumor may remain. Adding bevacizumab to paclitaxel is one therapeutic option to remedy these microenvironmental abnormalities if resistance occurs. In these case reports, we experienced effective tumor management with a long-term combination treatment of paclitaxel plus bevacizumab therapy. Here we introduce examples of typical cases that may have benefited by adding bevacizumab after paclitaxel refractory disease.

Case Presentation

Addition of bevacizumab to paclitaxel after treatment failure of weekly paclitaxel as first-line chemotherapy.

Case 1

A 70-year-old female was referred to our hospital for multiple lymph-node metastases in the right axilla, the right supraclavicular area, and the right parasternal region. She had a right mastectomy with axillary dissection followed by the sequence of anthracyclines and docetaxel in the adjuvant chemotherapy. The pathological diagnosis was invasive ductal carcinoma, which was positive for estrogen receptor (ER), negative for progesterone receptor (PgR), and positive for human EGFR-related protein. After four years of adjuvant hormonal treatment with anastrozole, lymph node metastases were revealed. After surgery and radiotherapy to remove the lesions, letrozole was administered as a re-adjuvant therapy. For other metastases that were later observed in the liver and lung, fulvestrant and a mammalian target of rapamycin inhibitors combined with exemestane was introduced sequentially over five years. A weekly paclitaxel monotherapy had been chosen as the first-line chemotherapy. After seven months of paclitaxel treatments, tumor markers, such as, carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3), were gradually elevated with a concurrent increase in the size and number of tumors in the liver. The patient received additional bevacizumab to paclitaxel. Although a dramatic shrinkage of the tumors was not observed, the tumor markers gradually reduced over the five month course of treatment (Figure 1). Paclitaxel plus bevacizumab is still being administered.

Case 2

A 50-year-old female developed lymph-node metastases in the right supraclavicular and parasternal regions, and multiple bone metastases were also later revealed in the thoracic and lumbar spine. She had undergone breast-conserving treatment with sentinel-node biopsy. The pathological diagnosis was invasive ductal carcinoma, which was ER positive, PgR positive, and HER2 positive. During three years of adjuvant hormonal therapy using luteinizing hormone-releasing hormone (LH-RH) agonists with tamoxifen, lymph-node metastases were observed. Although trastuzumab was tried, it was difficult to administer it continuously because of cardiac toxicity. Hormonal therapy including LH-RH and letrozole, zolendronic acid, and radiation treatment had been performed over five years to the bones, parasternal, and brain metastases. Weekly paclitaxel with zolendronic acid had been chosen as the first-line chemotherapy. After 16 months of paclitaxel, the tumor marker levels were elevated with evidence of disease progression by a computed tomography scan.
The patient received additional bevacizumab to paclitaxel. Although no dramatic shrinkage of the tumor was observed, tumor markers were gradually reduced over 12 months (Figure 2). Paclitaxel plus bevacizumab is still being administered. Addition of bevacizumab to paclitaxel after short-term recurrence (<6 months) following weekly paclitaxel as a neoadjuvant chemotherapy.

**Case 3**
A 45-year-old woman had been referred to our hospital due to a bulky lump in the left breast. After neoadjuvant chemotherapy using anthracyclines and weekly paclitaxel, a mastectomy and axillary dissection was performed. The pathological diagnosis was invasive ductal carcinoma, which was ER negative, PgR negative, and HER2 negative. During post mastectomy radiation therapy, left chest wall recurrence, lung metastases, and liver metastases were found. Weekly paclitaxel plus bevacizumab was administered. Although the interval between the paclitaxel monotherapy and paclitaxel plus bevacizumab was only three months, the tumor marker levels were reduced over four months until she refused further treatment due to various social reasons (Figure 3).

**Case 4**
A 42-year-old woman had been referred to our hospital due to left inflammatory breast cancer. After neoadjuvant chemotherapy using anthracyclines and weekly paclitaxel, a mastectomy and axillary node dissection was performed. The pathological diagnosis was invasive ductal carcinoma, which was ER negative, PgR negative, and HER2 negative. Two months after post mastectomy radiation therapy, left chest wall recurrence and lymph node metastases in the bilateral axilla, both in the parasternal regions, the left supraclavicular area, and the bilateral mediastinum regions were found. Weekly paclitaxel plus bevacizumab was administered. Although the interval between paclitaxel monotherapy and paclitaxel plus bevacizumab was only five months, tumor markers were reduced over the next five months until disease progression was later confirmed (Figure 4).

**Discussion**
Although a substantial benefit is expected with an addition of bevacizumab to standard chemotherapy in terms of OS [10], no clinical trials have demonstrated an OS advantage. In clinical practice, a taxane monotherapy such as weekly paclitaxel is frequently used as a first-line treatment because of the additional medical cost and potential toxicities such as proteinuria, hypertension, and cardiovascular events. The mechanism of efficacy with such low-dose chemotherapy was related to the tumor microenvironment, which may be different from standard chemotherapy with maximum doses.

In the tissue surrounding the tumor, the IFP is regulated by vascular permeability, lymphatic drainage, and the microvascular pressure, and tissue oxygen levels are also regulated by oxygen consumption, blood flow rate, and hemoglobin saturation in the blood vessels. In a neoadjuvant setting, weekly paclitaxel decreases the IFP and increases tissue oxygen levels, while such significant effects was not observed by a dose-dense doxorubicin containing regimen. A second-line treatment should be considered after treatment failure mainly caused by resistance to chemotherapy. Two mechanisms of drug resistance have been proposed: gene mutations, gene amplification, or epigenetic changes, which influence the uptake, metabolism, or export of a drug from cancer cells; and modification of the tumor microenvironment. The main mechanism of resistance to weekly paclitaxel may be associated with the tumor microenvironment, where tumors become hypervascular with the leaky vessels and the spatially and temporally heterogeneous blood flow. This leads to increased IFP and focal hypoxia, creating barriers to delivery and efficacy of therapeutics. Therefore, the addition of bevacizumab after resistance to weekly paclitaxel has the potential to be an important further treatment option. The proposed mechanisms of benefit from a combination of bevacizumab with chemotherapy include the inhibition of new-vessel formation, killing of immature tumor vessels, a transient normalization of the remaining vasculature by decreasing the IFP and hypoxia, and a possible synergic effect that

![Figure 2](image2.png)

**Figure 2:** CA15-3 serum concentrations during the course of paclitaxel plus bevacizumab following paclitaxel monotherapy for metastatic breast cancer.

![Figure 3](image3.png)

**Figure 3:** CEA serum concentrations during the course of paclitaxel plus bevacizumab for subsequent metastatic disease shortly after paclitaxel-containing neoadjuvant chemotherapy in patient with locally advanced breast cancer.

![Figure 4](image4.png)

**Figure 4:** CEA (—) and CA15-3 (—–) serum concentrations during the course of paclitaxel plus bevacizumab for subsequent metastatic disease shortly after paclitaxel-containing neoadjuvant chemotherapy in patient with inflammatory breast cancer.
leads to an enhanced direct cytotoxicity in some subsets expressing VEGF receptors [16].

In the E2100 trial, the median PFS after adding bevacizumab to weekly paclitaxel as a first-line treatment was extended from 5.9 to 11.8 months [4]. In our case series, bevacizumab plus paclitaxel could be administered for longer than six months (case 1) and 12 months (case 2) after a six month and 15 months weekly paclitaxel treatment, respectively. If paclitaxel therapy does not show any intolerable side effects, then the addition of bevacizumab with paclitaxel is a promising treatment option. According to a comparison of QOL outcomes during different chemotherapy lines, QOL shows a progressive deterioration over the chemotherapy lines [17]. Therefore, although no dramatic improvement was achieved, a relatively long treatment period by adding bevacizumab was observed in our case series, which may be associated with a good QOL.

**Conclusion**

Since there were no data showing crossover results to bevacizumab after disease progression in the chemotherapy-alone group, it was difficult to draw any conclusions from this retrospective case series regarding the efficacy of adding bevacizumab. Because bevacizumab is only allowed to be used with paclitaxel in Japan, this strategy of additional bevacizumab should be considered and may change clinical practices for patients with MBC.

**References**